Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in patients with moderate to severe hypertension.

Trial Profile

An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in patients with moderate to severe hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Amlodipine
  • Indications Hypertension
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2012 Primary endpoint mean seated systolic blood pressure has been met according to results published in the International Journal of Clinical Practice.
    • 01 Sep 2012 Results published in the International Journal of Clinical Practice.
    • 27 Aug 2010 FDA approval of Tekamlo was based on clinical trial data involving more than 5000 patients, including data from this study, according to a Novartis media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top